Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Kepal Patel

PharmaDeviceNews Kepal Patel

Medical Devices & Diagnostics

Pulse Biosciences (PLSE) reports 86% thyroid nodule response, but can the results hold?

by Pallavi Madhiraju
November 6, 2026
0 Comments

Pulse Biosciences reports an 86% thyroid nodule response in PRECISE-BTN. See what the interim data mean for clinical adoption.

Read More

Latest news and features

Thermo Fisher Scientific’s new $5bn buyback: A confidence signal or capital allocation test?
Bio-Thera’s BAT2506 wins a China first, but can it challenge Johnson & Johnson’s Simponi?
Stents, kidney disease and heart failure AI: What could NYU Langone’s AHA 2026 data reveal?
BRC Therapeutics hires Jazz Pharmaceuticals veteran, but can its cannabinoid pipeline deliver?
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Revelation Biosciences sees a $94bn Gemini market, but can it fund the clinical test?
MaaT Pharma’s PICASSO trial met its primary goal, so why is the melanoma efficacy picture still uncertain?
Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?
Onkos Surgical expands NanoCept again, but can antibacterial implants prove their clinical value?
Raidium brings Stanford’s Curtis Langlotz on board, but can its AI earn radiologists’ trust?
Pulse Biosciences (PLSE) reports 86% thyroid nodule response, but can the results hold?
Network Bio’s Duke University deal targets a critical gap in medical AI: What happened to patients?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

TC Energy approves C$3bn pipeline projects as AI power demand drives gas expansion
Cloudflare revenue jumps 39% to $782.5m, but GAAP losses raise a bigger question
US expands Cuba sanctions to technology, shipping and manufacturing sectors
Freeport-McMoRan (FCX) approves $4.5bn copper expansion as shares fall 7.5%
Adani Ports (ADANIPORTS) targets Evos in €2.56bn deal, but can debt-funded expansion deliver returns?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.